The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Read a summary of the causes Alzheimer's disease, inclouding neurofibrillary tangles, inflammation, vascular and environmental factors, genetics and aging.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Learn more about the symptoms of Alzheimer’s disease, the most common form of dementia, and its several stages. Alzheimer's symptoms may be different for each patient.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today